亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

T2 Biologics for Chronic Obstructive Pulmonary Disease

医学 重症监护医学 肺病 内科学 梅德林 慢性病 政治学 法学
作者
Ahmed Yousuf,Wadah Ibrahim,Neil Greening,Christopher E. Brightling
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:7 (5): 1405-1416 被引量:47
标识
DOI:10.1016/j.jaip.2019.01.036
摘要

Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third leading cause of death and disability worldwide by 2030. Recent advances in understanding the underlying pathophysiology of COPD has led to the development of novel targeted therapies (biologics and small molecules) that address the underlying pathophysiology of the disease. In severe asthma, biologics targeting type 2 (T2)- mediated immunity have been successful and have changed the treatment paradigm. In contrast, no biologics are currently licensed for the treatment of COPD. Those targeting non-T2 pathways have not demonstrated efficacy and in some cases raised concerns related to safety. With the increasing recognition of the eosinophil and perhaps T2-immunity possibly playing a role in a subgroup of patients with COPD, T2 biologics, specifically anti–IL-5(R), have been tested and demonstrated modest reductions in exacerbation frequency. Potential benefit was related to the baseline blood eosinophil count. These benefits were small compared with asthma. Thus, whether a subgroup of COPD sufferers might respond to anti–IL-5 or other T2-directed biologics remains to be fully addressed and requires further investigation. Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third leading cause of death and disability worldwide by 2030. Recent advances in understanding the underlying pathophysiology of COPD has led to the development of novel targeted therapies (biologics and small molecules) that address the underlying pathophysiology of the disease. In severe asthma, biologics targeting type 2 (T2)- mediated immunity have been successful and have changed the treatment paradigm. In contrast, no biologics are currently licensed for the treatment of COPD. Those targeting non-T2 pathways have not demonstrated efficacy and in some cases raised concerns related to safety. With the increasing recognition of the eosinophil and perhaps T2-immunity possibly playing a role in a subgroup of patients with COPD, T2 biologics, specifically anti–IL-5(R), have been tested and demonstrated modest reductions in exacerbation frequency. Potential benefit was related to the baseline blood eosinophil count. These benefits were small compared with asthma. Thus, whether a subgroup of COPD sufferers might respond to anti–IL-5 or other T2-directed biologics remains to be fully addressed and requires further investigation. Biologics, Clinical Context, and the AsthmasThe Journal of Allergy and Clinical Immunology: In PracticeVol. 7Issue 5PreviewIt has been more than 15 years since the US Food and Drug Administration approved omalizumab for the therapy of moderate-to-severe perennial allergic asthma. The concept of removing one of the key triggers of asthma, IgE, excited the scientific and medical community. Indeed, with 80% of children and 50% of adults having a significant allergic trigger to their asthma, it was envisioned that this approach could lead to long-standing remission or perhaps even a cure for many patients. Moreover, serum IgE levels had been shown to be increased in smokers, implicating a potential role for IgE in the pathogenesis of smoking-related lung diseases such as chronic obstructive pulmonary disease (COPD). Full-Text PDF CME Exam: T2 Biologics for Chronic Obstructive Pulmonary DiseaseThe Journal of Allergy and Clinical Immunology: In PracticeVol. 7Issue 5Preview Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
GYQ发布了新的文献求助10
刚刚
GYQ完成签到,获得积分10
7秒前
淡定的雁玉完成签到 ,获得积分10
9秒前
36秒前
FashionBoy应助兴奋的嘉懿采纳,获得10
56秒前
1分钟前
祖之微笑发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
1分钟前
2分钟前
2分钟前
2分钟前
祖之微笑发布了新的文献求助10
2分钟前
简因完成签到 ,获得积分10
2分钟前
英姑应助苹果果汁采纳,获得30
2分钟前
kaka完成签到,获得积分10
2分钟前
2分钟前
Jason发布了新的文献求助10
3分钟前
3分钟前
3分钟前
量子星尘发布了新的文献求助10
3分钟前
小乘号子发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
子平完成签到 ,获得积分0
3分钟前
科研通AI5应助哲别采纳,获得10
4分钟前
gszy1975完成签到,获得积分10
4分钟前
小乘号子发布了新的文献求助10
4分钟前
4分钟前
Akim应助小乘号子采纳,获得10
4分钟前
量子星尘发布了新的文献求助10
4分钟前
yi完成签到,获得积分10
4分钟前
英俊的铭应助执着的草丛采纳,获得10
5分钟前
科研通AI2S应助科研通管家采纳,获得10
5分钟前
slayers完成签到 ,获得积分20
5分钟前
Billy完成签到,获得积分0
5分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976665
求助须知:如何正确求助?哪些是违规求助? 3520756
关于积分的说明 11204771
捐赠科研通 3257528
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629